Matches in Wikidata for { <http://www.wikidata.org/entity/Q92380610> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q92380610 description "2019 թվականի մարտի 11-ին հրատարակված գիտական հոդված" @default.
- Q92380610 description "article scientifique publié en 2019" @default.
- Q92380610 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q92380610 description "im März 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92380610 description "scientific article published on 11 March 2019" @default.
- Q92380610 description "wetenschappelijk artikel" @default.
- Q92380610 description "наукова стаття, опублікована 11 березня 2019" @default.
- Q92380610 name "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies" @default.
- Q92380610 name "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies" @default.
- Q92380610 type Item @default.
- Q92380610 label "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies" @default.
- Q92380610 label "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies" @default.
- Q92380610 prefLabel "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies" @default.
- Q92380610 prefLabel "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies" @default.
- Q92380610 P1433 Q92380610-9BB9DB5C-2B7F-4B67-8499-809DBD418D25 @default.
- Q92380610 P1476 Q92380610-4F2A18F0-66D8-4689-A04C-15C8EEF5844A @default.
- Q92380610 P2093 Q92380610-507C5623-37CE-4D0C-9DB3-987A86D9B46F @default.
- Q92380610 P2093 Q92380610-8710A978-BF66-4141-B598-7D981BCCFA52 @default.
- Q92380610 P2093 Q92380610-8CB31AE6-DC1E-46FF-8B23-4C0AC1EBD207 @default.
- Q92380610 P2093 Q92380610-AC761BBA-6DEF-4634-8989-95057C4310F4 @default.
- Q92380610 P2093 Q92380610-B63B1EC2-B7DF-47A9-AF06-D929016C2D26 @default.
- Q92380610 P2093 Q92380610-B9CB198C-57CA-4ACE-9E81-22B1E0A1AC07 @default.
- Q92380610 P2093 Q92380610-C2837A82-869B-42C0-890C-99AB66EB94E6 @default.
- Q92380610 P2093 Q92380610-E609C056-AF70-456B-B1AB-85831172057E @default.
- Q92380610 P304 Q92380610-1D172C46-263A-4BB8-AF5D-B80D49BF01ED @default.
- Q92380610 P31 Q92380610-AD08FC57-4FB9-44B6-9385-30711574266A @default.
- Q92380610 P433 Q92380610-85DEFF1E-9870-436A-986D-54B259125269 @default.
- Q92380610 P478 Q92380610-99323793-4CD6-4B1A-AC0B-87AB5E255A84 @default.
- Q92380610 P577 Q92380610-74C7FF6C-8599-4CF7-A12E-5BFF0E05A022 @default.
- Q92380610 P698 Q92380610-F9B70857-FA5D-484B-AD46-1AC881D4A53C @default.
- Q92380610 P921 Q92380610-65FD4316-8FD0-4260-AA2C-707DD41B22AD @default.
- Q92380610 P921 Q92380610-809F6B04-4528-480B-96EC-297D116C21B5 @default.
- Q92380610 P698 30873952 @default.
- Q92380610 P1433 Q15759225 @default.
- Q92380610 P1476 "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies" @default.
- Q92380610 P2093 "Diana M Verboom" @default.
- Q92380610 P2093 "Jan A M van Laar" @default.
- Q92380610 P2093 "Jasper H Kappen" @default.
- Q92380610 P2093 "Marco W J Schreurs" @default.
- Q92380610 P2093 "P Martin van Hagen" @default.
- Q92380610 P2093 "Paul L A van Daele" @default.
- Q92380610 P2093 "Tim B van der Houwen" @default.
- Q92380610 P2093 "Willem A Dik" @default.
- Q92380610 P304 "43-47" @default.
- Q92380610 P31 Q13442814 @default.
- Q92380610 P433 "6" @default.
- Q92380610 P478 "37 Suppl 121" @default.
- Q92380610 P577 "2019-03-11T00:00:00Z" @default.
- Q92380610 P698 "30873952" @default.
- Q92380610 P921 Q348260 @default.
- Q92380610 P921 Q911427 @default.